Showing posts with label transplantation. Show all posts
Showing posts with label transplantation. Show all posts

Monday, October 19, 2026

Moral Economics reviewed in American Journal of Transplantation

 I wonder if this is the first time an economics book has been reviewed in the American Journal of Transplantation.

Poetic justice: A review of moral economics by Alvin E. Roth
Michael A. Rees

 "Alvin E. Roth describes poetic justice as the Virginia state flag flying at half-mast in 2020 in honor of Bernie Cohen, who argued the US Supreme Court case Loving v. Virginia that made interracial marriage legal. Turns out Mildred and Richard Loving were convicted of interracial marriage in 1967, arrested by police at 2 AM at home in their bed, and sentenced to 1 year in prison but suspended on the condition that they leave Virginia for 25 years. Reading what the Virginia Court of Appeals judge wrote, side by side with what the US Supreme Court wrote, is, by itself, worth the price of the book.
 

"Those of us in the field of transplantation have felt—and will continue to feel—the impact of repugnance. In moral economics, Alvin E. Roth takes us on a grand tour of how repugnance shapes transactions across a wide spectrum of human activities. Take uterus transplantation, pioneered in Sweden, a country where repugnance to surrogacy has made it illegal. You can transplant a uterus into a woman with infertility in Sweden, but do not you dare use a surrogate’s uterus in her own body to help you achieve a baby! Alvin E. Roth defines repugnance as a morally contested market that some people would like to participate in, but others think should be outlawed. He goes on to call a transaction repugnant if “all parties to the transaction want to engage in it, and others think they shouldn’t be allowed to for moral or religious reasons, even though those others can’t detect that the transaction has taken place unless someone tells them.”1 I found it fascinating to walk through all the ways in which repugnance has shaped the world in which we live.
 

"The book starts with a clear example of a transaction that many people want to engage in: sex. Of course, I knew about the repugnance surrounding prostitution and pornography, but could hardly believe the stories of how far people go on either side of a repugnant transaction. I found my own views challenged by what I thought was right, especially when considering the outcome I desired from the controversy being described. It was interesting to have these stories told by the “Father of Market Design” and to think about sexual desire as a contested marketplace with good and bad outcomes that could be influenced by better market design.
 

"It is not the first time I have been surprised to think about a human desire for something like love or health as a transaction that economists could study. I first met Alvin E. Roth in about 2004 when he thought he could help us transplant professionals do a better job with kidney exchange. I made the mistake of thinking that economists only worried about money, albeit at both the microlevel and macrolevel. This book makes clear that if we want to have the desired outcome of helping as many people as possible through organ transplantation, we are going to have to think like market designers and overcome repugnance to innovation. Remember Richard Lower in 1968 being threatened with criminal charges for “wrongful death” for removing a donor heart prior to the establishment of brain death criteria?
 

"My favorite chapter was about reproduction. You would not believe all the interesting twists and turns that have happened as artificial reproductive technology has blossomed, and some people wanted to have babies using it, whereas others were morally aghast at their desire, working hard to stop them. It was interesting to see different sides of contraception, abortion, in vitro fertilization, egg and sperm donation, paternity, maternity, parenthood, and surrogacy. But Alvin E. Roth has such a nice way of distilling complicated concepts, such as this quote: “Some critics have said that looking for an egg donor who attends Harvard, for example, reeks of eugenics. In response to that, Professor Kim Krawiec, perhaps the leading legal scholar of “taboo trades,” gave a very cogent response: “Fertile people have been screening for beauty and intelligence for years and years. It’s called dating.”2
 

"If transplantation attracted you as a field in part because of the ethical challenges encountered when considering organ donors and recipients, Moral Economics provides a narrated guide through thorny issues. Near the end of the book, we find perhaps the best call to action for those of us who want to solve problems. The Persian poet Rumi invites us to navigate repugnance: “Out beyond ideas of wrongdoing and rightdoing, there is a field. I’ll meet you there.”3
 
1. Roth, A.E.
Moral Economics: From Prostitution to Organ Sales, What Controversial Transactions Reveal About How Markets Work. Hachette UK; 2026
2026

2. Jones, A. Putting a Price on a Human Egg.”
Wall Street Journal. July 26, 2015;
Accessed XXX www.wsj.com/articles/putting-a-price-on-a-human-egg-1437952456


3.Rumi, “Out Beyond Ideas of Wrongdoing and Rightdoing.” Poetry Society of America. 

Tuesday, October 13, 2026

The University of Cincinnati celebrates Steve Woodle

Dr. Steve Woodle, one of the pioneers of kidney exchange, is being honored in Cincinnati.  You can read of his many distinctions below, but here's a striking one: he is the "the first liver transplant recipient to perform a liver transplant."

2026 Daniel Drake Medals  The University of Cincinnati College of Medicine’s highest honor 

E. Steve Woodle, MD

Professional portrait of E. Steve Woodle, MD

E. Steve Woodle, MD

Woodle, professor of surgery and the William A. Altemeier endowed chair in surgery at the College of Medicine, is a multiorgan transplant surgeon and transplant immunologist who has spent more than four decades advancing the understanding of organ rejection and pioneering immunosuppressive therapies that have reshaped transplantation. Earlier in his career at the University of Chicago, he performed a liver transplant on a 10-day-old infant, setting a Guinness World Record for the youngest liver transplant recipient. He joined the College of Medicine in 1999 and directed the Division of Transplantation for nearly two decades, building an internationally recognized program of clinical and research excellence. In 2001, he performed Ohio’s first allogeneic islet transplant for type 1 diabetes. After undergoing his own liver transplant in 2003, Woodle returned to the operating room and became the first liver transplant recipient to perform a liver transplant.

Woodle has helped originate several therapeutic approaches now considered standard in transplantation. As a fellow, he conceived the genetic re-engineering of OKT3, the first FDA-approved monoclonal antibody — work later developed into teplizumab (Tzield), which the FDA approved in 2022 as the first immunomodulatory therapy for type 1 diabetes. He was the first investigator to introduce plasma cell-targeted therapy for a non-malignant human disease, using proteasome inhibitors to treat antibody-mediated rejection in kidney transplant recipients. He also pioneered corticosteroid-free immunosuppression, including the field’s landmark double-blind, placebo-controlled trial of early corticosteroid withdrawal. He helped conceive and establish clinical kidney exchange for incompatible living-donor pairs, publishing the field’s first peer-reviewed description in the New England Journal of Medicine in 1997. Kidney exchange now accounts for roughly one in five living-donor kidney transplants in the U.S.

His scholarship includes more than 400 scientific publications cited more than 22,000 times, and he has delivered more than 700 invited lectures and mentored generations of transplant surgeons, physicians and pharmacists. In 2025, he received the American Society of Transplantation’s Senior Achievement Award in Clinical Transplantation and was named an Ashbel Smith Distinguished Alumnus by the University of Texas Medical Branch, where he earned his medical degree.

Featured photo at top: Daniel Drake Medal. Photo/University of Cincinnati.

 

Wednesday, October 7, 2026

The first 100 cases of organ donation after euthanasia in the Netherlands

 Here's a controversial market with something for everyone to argue about: organ donation after euthanasia, including psychiatric patients, in the Netherlands.

van Dijk, N., Wijffels, S., Wind, T. et al. The first 100 cases of organ donation after euthanasia in the Netherlands: lessons from preliminary experiences. BMC Med Ethics (2026). https://doi.org/10.1186/s12910-026-01590-5 

"Background
Organ donation after euthanasia (ODE) is an evolving, patient-initiated procedure in the Netherlands. While it gives meaning to donors at the end-of-life, it introduces complex ethical and practical challenges for healthcare professionals. This study aims to describe the clinical characteristics and donation outcomes of the first 100 ODE procedures in the Netherlands, while outlining the practical and ethical dilemmas encountered.

Methods
A retrospective analysis was performed on prospectively collected data from the first 100 ODE procedures conducted between September 2012 and February 2023. To gain deeper insight into practical experiences and ethical themes, these data were discussed with organ donation coordinators and intensivists involved in the procedures. The analysis focused on clinical characteristics and donation outcomes, as on ethical and practical challenges.

Results
Neurodegenerative disorders were the primary underlying cause of suffering (52%), followed by psychiatric conditions (31%). The first 100 procedures resulted in 408 transplanted organs. Most procedures were performed in intensive care units, with general practitioners performing euthanasia. Key ethical and practical challenges included the tension between clinical protocols (e.g., fasting) and patient comfort, the medicalisation of the dying process through invasive monitoring, and the logistical barriers of starting ODE from home (ODEH). Furthermore, ethical concerns persist regarding euthanasia in psychiatric and dementia cases, and the emotional burden on healthcare professionals.

Conclusions
Patient-initiated ODE is feasible and allows patients to fulfil altruistic end-of-life wishes, but introduces complex ethical and practical challenges. Balancing organ donation with a dignified, non-medicalised death requires careful planning, especially as ODE expands to psychiatric and early dementia cases. Healthcare professionals face emotional and logistical burdens, yet are motivated by the positive impact on donors and recipients. Insights from these initial cases contributed to the development of the 2024 Dutch guideline, which supports both local and centralised procedures and which removed distinctions between somatic and psychiatric suffering. Further research should explore relatives’ perspectives to understand the broader impact of ODE(H). "

Saturday, September 26, 2026

Organ trafficking research

 Frederike Ambagtsheer is the principal investigator of a Dutch project conducting organ trafficking research, whose website discusses their work:

welcome to organ trafficking research

This platform presents research projects on the human organ trade that are conducted by Erasmus MC's Organ Trafficking Research Group. We further provide information for interested audiences (e.g. students, researchers, law enforcement, law -and policy-makers, etc) about the complexities of this crime and the responses there-to.

The organ trafficking research group is based at Erasmus MC's Department of Internal Medicine, Section Nephrology and Kidney Transplantation in Rotterdam(opens in new tab), The Netherlands. This department is part of the recently established Erasmus MC Transplant Institute (opens in new tab)which houses one of the largest kidney transplantation centers in Europe.

...

what we do

We are an enthusiastic and dedicated team of researchers that conduct empirical research on different facets of organ trade and trafficking. Our research is structured into various projects. Methods include a mix of qualitative and quantitative research strategies including systematic literature reviews, surveys, ethnographic research, crime scripting and network analysis.

We conduct research in countries across the globe and we focus on all stages of the organ trading chain, including organ buying, selling, the organisation of illegal transplants and law enforcement responses. We also explore alternative measures such as allowing financial rewards for organ donation. In addition, we advise governments and (inter)national organizations on how to address organ trade problems.

Our research is funded by organisations including the European Commission, the European Research Council and the Dutch Research Council (NWO)."

 

 

Saturday, September 19, 2026

A passionate proponent of transplants is (temporarily) unregistered as a donor: Greg Segal in the NYT

I'm a little shaken to learn that (even*) Greg Segal has temporarily suspended his registration as a potential deceased organ donor.  My registration remains active, but I'm watching with attention the regulatory and other reforms that are being contemplated for the system of deceased donation in the U.S.

What I Found Out About Organ Donation Shocked Me
By Greg Segal
Mr. Segal is the founder and chief executive of Organize, a nonprofit focused on reforming the organ donation system. 

 "I founded Organize, a nonprofit making it easier to register to become an organ donor. In 2015, Organize was selected for a role embedded inside the U.S. Department of Health and Human Services, which put us on the radar of whistle-blowers. I soon became inundated with allegations from people working inside the organ donation industry who felt they had nowhere else to turn.

"I know as well as anyone that organ donation saves lives — over 40,000 annually in the United States in recent years. But I was stunned to learn that organ procurement organizations — the federal contractors that coordinate organ donation from the deceased — that made those transplants possible were routinely violating ethical standards and putting patients at risk.

"I heard allegations of negligence and financial fraud, including industry executives’ billing taxpayers for joyrides on private jets meant to transport organs; of organizations performing unnecessary procedures as part of a scheme to overbill Medicare. (Organ procurement organizations are nonprofits, but that doesn’t mean they aren’t trying to maximize financial reimbursements.) I’ve heard of poorer Americans waiting to receive organs passed over in favor of wealthier ones.

"But one case in particular led me to remove myself from the donor registry and testify before Congress."

#######

He goes on to recount one of the most disturbing cases reported recently in the NYT (which I think were at least in part uncovered through the work of his Organization).

See

Friday, June 6, 2025 Disturbing NYT report about an Organ Procurement Organization in Kentucky

 and

Sunday, July 20, 2025  Organ donation after circulatory death: the NYT recounts some disturbing cases

also

*Saturday, August 9, 2025  Withdrawals from deceased donor registries   

Monday, September 7, 2026

A.I. in health care in Paris

Here's tomorrow's conference agenda for the opening day of the  Redefining Health Care in the Age of A.I. conference in Paris.  Philippe Aghion will speak on "Should we fear AI?"
My talk is about  "Computational Intelligence and Organ Allocation on a Global Scale."

Day 1 – Tuesday 8 September

8:00 am
Opening of the Sorbonne
8:15 am
Attendee registration and welcome coffee with viennoiseries
9:15 am
Introduction by Nature Editors and PITOR Institute
Magdalena Skipper, Joao Monteiro and Alexandre Loupy
9:40 am
Day opening lecture: Should we fear AI?
Philippe Aghion – Nobel Prize Laureate
Chaired by Magdalena Skipper
10:20 am
Keynote: Computational Intelligence and Organ Allocation on a Global Scale
Alvin Roth – Nobel Prize Laureate
Chaired by Alexandre Loupy
11:00 am
Imaging and diagnostic models
Chaired by Alexandre Loupy and Sadra Bakhshandeh
11:00 am
From Pixel to Patient: AI for Multimodal Medical Imaging
Julia Schnabel
11:30 am
Foundation models bridging molecular information and pathology
Guangyu Wang
12:00 pm
Building Trustworthy AI for Clinical Decision-Making
Roxana Daneshjou
12:30 pm
Short Talk Presentation (selected from submitted abstracts)
Disparate privacy risks from medical AI: a new axis of health inequality
Moritz Knolle, Technical University of Munich (TUM)
12:45 pm
Lunch break
2:15 pm
Meet the Nature editors
Joao Monteiro, Magdalena Skipper, George Caputa, Lorenzo Righetto, Monica Wang, Ananya Rastogi, Sadra Bakhshandeh and Wanying Wang
3:15 pm
Keynote: Towards conversational diagnostic artificial intelligence
Alan Karthikesalingam
Chaired by George Caputa
3:55 pm
Coffee break
4:30 pm
Foundation models and drug discovery
Chaired by Roxana Daneshjou and George Caputa
4:30 pm
Six Aging Clocks Confirmed Biological Age Reversal in Phase IIa Trial of a Novel Therapeutic Discovered Using Aging Research and Generative AI
Alex Zhavoronkov
5:00 pm
Building AI for Biological Reasoning: Towards Biological Artificial Superintelligence
Thomas Clozel
5:30 pm
Short Talk Presentation (selected from submitted abstracts)
When AI meets the emergency department: rethinking how we evaluate clinical AI
Austin Schoeffler, Stanford University
5:45 pm
Short Talk Presentation (selected from submitted abstracts)
Testing levels of LLM agent autonomy in inpatient treatment decisions: a prospective, silent-mode evaluation of vancomycin dosing
Yixing Jiang, Stanford University & Kameron C. Black, Stanford Health Care
6:00 pm
Roundtable: Opportunities and limits in implementing AI in healthcare
Effy Vayena, Demilade Adedinsewo, Jessilyn Dunn, James Zou, and Marco Marsella

Moderated by Alexandre Loupy and George Caputa
7:00 pm
Poster session with wine and cheese

 

Saturday, September 5, 2026

Redefining Healthcare in the Age of A.I., Paris, Sept 8-10

 I'm in Paris, for the conference Redefining Healthcare in the Age of AI 

"The Paris Institute for Transplantation and Organ Regeneration (PITOR) is delighted to announce the first Nature Conference in Europe dedicated to artificial intelligence in medicine, taking place in Paris from 8–10 September 2026.

Held under the High Patronage of the President of the French Republic, the conference will bring together 28 leading international experts, including two Nobel Prize laureates, as well as the Editors-in-Chief of Nature, Nature Medicine, Nature Reviews Engineering, Nature Reviews Nephrology, and Nature Health. The meeting will be held in the historic amphitheater of the Sorbonne.

Topics will include:

    Medical imaging and diagnostics
    Ethics and regulation
    Medical robotics and wearable technologies
    Agentic AI and clinical decision support
    Drug discovery and repurposing
 

Thursday, August 20, 2026

How heart transplants gave birth to brain death (new book by Basil Baccouche)

 Basil Baccouche has a forthcoming book, which I found pretty thrilling:

The End of Death: A Surgeon, a Heart Transplant, and the Fight to Change What It Means to Die

 

Here's my blurb for the book:

 “Basil Baccouche is a new star in the constellation of physicians who write. The End of Death tells the gripping story of a tireless doctor (Norman Shumway), a drug (cyclosporine), and a law (recognizing brain death) that combined to make heart transplants one of the miracles of modern medicine.” 

Tuesday, August 18, 2026

Public attitudes towards deceased organ donation and allocation in china

 Deceased  organ donation in China does not  yet have overwhelming public support although receiving a deceased donor organ transplant does:

Hu, D., Wang, Y., Hu, Q. et al. Public attitudes and preferences on organ donation and allocation in china: a cross-sectional study. Sci Rep 16, 24995 (2026). https://doi.org/10.1038/s41598-026-54903-4 

 

 

 

Monday, August 10, 2026

Deceased organ donation by Ashlagi and Roth in the Annual Review of Economics (with open questions)

 Here's a review paper concentrating primarily on transplantation of  organs (primarily kidneys) from deceased donors. It closes with a set of open research questions.


Organ Allocation and Transplantation
  by Itai Ashlagi and Alvin E. Roth,  Annual Review of Economics, Volume 18, 2026, Vol. 18:613-645, August 2026, https://doi.org/10.1146/annurev-economics-092425-123425     
 
ABSTRACT: There is a large shortage of solid organs for transplants. This survey reviews the allocation of organs (particularly kidneys), with an emphasis on how deceased donor organs are obtained and allocated in the United States but with pointers to related issues involving living donors and transplantation around the world. We review some of the key institutional details and theoretical and empirical studies and describe some open questions that we hope will continue to attract attention from researchers interested in the economic and operational aspects of organ allocation.

 
1. INTRODUCTION
 "Since at least the turn of the century, organ transplants have attracted considerable interest from economists. This is due both to their importance in modern medicine and to the fact that organ transplantation deals directly with some of the most basic questions of economics—namely, how to efficiently allocate scarce resources and how to make them less scarce. "

...

OPEN QUESTIONS AND RESEARCH DIRECTIONS
 
This section highlights research opportunities, some of which have been raised above.

1.  Can we design allocation rules free of justified envy that place hard-to-match organs quickly enough so that they remain transplantable? A large number of recovered organs that might be transplanted are discarded. How can we increase utilization of marginal-quality organs and get them accepted after fewer offers and less CIT? How can we do this in a transparent and equitable way? How can we use the information about organ quality that arrives during the offering process? 91 How can we use offer refusals in real time? How should we design allocation rules in the presence of social learning and potential information cascades (Zhang 2010, Doval et al. 2024)? How should the variability in centers’ willingness to accept marginal organs be accounted for?
2.  How to design priorities to balance efficiency and equity? How can priorities be designed to account for both longevity and urgency (Zhang et al. 2024, Lazenby et al. 2025)? How can priorities depend on patients’ treatments, taking into account that treatment decisions may in turn depend on priorities (Sweat 2023)? Countries use different priority rules, and there is a need to compare these to better understand trade-offs between these rules. The OPTN is seeking to implement continuous distribution allocation policies for hearts and kidneys, which will assign priority points smoothly across patient and match features. There are not yet studies that offer guidance to the resulting (in)efficiencies. 92
3.  How should organ quality be measured and reported? The KDPI is currently used for both acceptance decisions by surgeons and prioritization in the allocation system. As supply changes over time, percentiles correspond to different qualities. For example, a KDPI of 85% (which is the threshold for requiring patient consent to receive an offer) in 2018 corresponds to (i.e., has the same underlying nonnormalized KDRI risk measure as) a KDPI of 75% in 2024 due to the recovery of more organs and therefore the higher availability of organs of marginal quality. Would the use of the nonnormalized KDRI substantially change behavior and outcomes?
4.  How should surgeons’ and patients’ preferences be elicited? The OPTN allows transplant centers to express preferences via filters that screen organ offers. Despite this, many organs are still declined hundreds and even thousands of times (Agarwal et al. 2021, Guan et al. 2025). How can we better design these filters? Can we use AI to help recommend filters or to predict organ refusals in real time? More broadly, how should waitlist mechanisms be designed given incomplete patient and center preferences?
5.  How should transplant centers’ performance be measured? Should transplant centers be incentivized to accept marginal organs, for example, for patients facing many years of dialysis? How should we regulate transplant centers? Are new incentive schemes useful in increasing utilization? For example, how will the acceptance rate and pre-transplant mortality rate metrics impact centers’ behavior? The CMS has also launched the Increasing Organ Transplant Access model, 93 using a long-term field experiment that offers monetary incentives based on the number of transplants performed, graft survival, and percentage of accepted offers (Chan & Roth 2026.) How should we incorporate the huge role that transplant centers play in acceptance/rejection decisions when studying organ allocation mechanisms (Chan & Roth 2024, Ashlagi et al. 2025a)? There is a need for research on designing centers’ performance measures that include outcomes for patients on the waiting list.
6.  How should OPO performance be measured? OPOs vary in performance in terms of organ recovery and utilization, and incentive schemes remain controversial. How effective is the new tier system for monitoring OPOs based on donation and age-adjusted transplant rates? How should OPOs be incentivized to improve performance and transparency and to coordinate with transplant centers (see Chan & Roth 2024, Bae et al. 2026, Skowronski et al. 2026)?
7.  What should we incorporate in transplant centers’ preferences? Most theoretical models treat patients as the decision makers who accept or reject organ offers. In practice, however, transplant centers exercise substantial discretion over acceptance decisions, listing practices, and setting filters. How do equilibrium outcomes reflect centers’ preferences? There is a need for empirical and theoretical studies of how centers’ characteristics and incentives shape outcomes.
8.  Can we design simulation tools that account for equilibrium behavior? Simulations and historical data have been instrumental to the study and design of allocation policies. Existing simulations apply myopic acceptance models that are invariant to the allocation rules. There is a need for simple modern simulation tools that account for the incentives of patients and centers. 94 It would be interesting to create tools that generate not only better equilibrium predictions but also short-term equilibration effects. 95
9.  What kinds of experiments should the OPTN conduct? The OPTN conducts very few controlled experiments, despite facing ongoing allocation policy decisions. While simulation tools are useful to inform policy, field experiments offer another approach. Experiments can generate useful data to evaluate different approaches (e.g., for expediting placements). The size and heterogeneity of the United States present opportunities to test different approaches; but they also raise questions about whether different approaches would work differently in different regions, and about how to overcome the reluctance to conduct experiments.
10.  How can countries with low transplant rates be helped? Many countries have low living and/or deceased donation rates. Understanding the underlying barriers (organization structure, population preferences, etc.) would be fruitful in making progress toward increasing transplant rates (see, e.g., Okubo et al. 2026).
11.  What can be done to increase incentives for organ donation in ways that attract social support? What accounts for the widespread reluctance to increase organ donation by compensating donors? How can economists better explain the value of incentives in addressing scarcity and gather persuasive evidence to engage in a productive dialog with those who fear that this will increase rather than decrease black markets, or who feel there are fundamental religious or ethical objections to compensating organ donation? [For some thoughts on this, readers are referred to Roth (2026b)]. 

Friday, July 31, 2026

Delayed feedback on a controversial talk--and some positive signals of potential for change

 One feature of giving talks to unfamiliar audiences is that you only get noisy feedback on how your talk was received.  This past June, I gave the Starzl Lecture at the American Transplant Congress in Boston. (The ATC is jointly organized by the two big American transplant societies, the AST and the ASTS,*)  I spoke to an audience of about 1500 people (just a guess, but I could see some empty seats in an auditorium set up for 2,000).  My talk included topics, including global kidney exchange, that have raised controversies.  

Afterwards, what seemed like a lot of people came to speak to me, and were enthusiastic about my talk.  But "a lot of people" was fewer than 100. So what about everyone else? (It probably wouldn't be statistically kosher to assume that those who came to congratulate me were a representative sample:)   

Since global kidney exchange has led to some people calling me an organ trafficker, I didn't have any measure of the general sentiment of the meeting.

I got some reassuring news recently when the ATC sent out an email soliciting ideas for talks for next year's meeting, in Seattle.  The email came with a picture from this oat meeting:

 

 So I'm guessing this means that my talk was well received by people responsible for organizing the next meeting.

And, indeed, I'm getting multiple signals that there's an appetite for productive change in the transplant community.  I hope to have more to say about that in the coming year.

######

*Acronyms:

ATC American Transplant Congress 

 AST American Society of Transplantation

ASTS American Society of Transplant Surgeons 

Monday, June 22, 2026

A rogue's gallery of transplant heroes (following ATC2026)

 After my talk yesterday at the American Transplant Congress, I had lunch with a table of transplant heroes, Joe Tector, Peter Friend, Juliana Bastos, Mike Rees and Gustavo Ferreira.

 

 

 

 

 

 

Friday, June 19, 2026

Starzl Lecture: "The Economics of Kidney Exchange," Sunday at the American Transplant Congress in Boston

 I'll be speaking Sunday at the American Transplant Congress, on kidney exchange.  It will be hard to squeeze in all the recent developments in my half hour, including current controversies.


State-of-the-Art Speakers:  Transplantation’s leading luminaries and innovative thinkers will share inspiring research and insights at ATC 2026.  
 
Alvin E. Roth, PhD: 
Thomas E. Starzl State-of-the-Art Lecture: The Economics of Kidney Exchange

Sunday, June 21: 11:00 AM ET 

 

 

 

Monday, June 1, 2026

The American Society of Transplantation prepares to consider a pilot study of financial incentives for living organ donation

 As I prepare to speak later this month at the American Transplant Congress in Boston, I note that  the American Society of Transplantation (AST) has, among its Key Position Statements  one from late last year called A Roadmap for Removing Disincentives for Living Organ Donors 

As the title suggests, the statement focuses on removing financial disincentives for organ donation. 

But I'm struck by the last item on the list:

"Additional Steps
"In advocating for the elimination of disincentives to living donation, AST will examine, in parallel, the legal,ethical, and practical considerations involved in a pilot study of financial incentives for living organ donation."

  

Monday, May 18, 2026

Kidneys and Moral Economics in the Financial Times

I spoke about economics with Keynes (Soumaya) in the FT:

Nobel laureate Al Roth and the economics of organ sales  
 "The economist Alvin Roth been talking about kidneys since at least 2003, noting time and again that kidneys are in short supply, waiting lists are growing longer, and people are dying as a result.
 

"So why is Roth — who appears on this week’s episode of the Economics Show podcast — still banging on about kidneys? Well, because all of those things are still getting worse."

Here is the podcast:

FT Podcast  The Economics Show with Soumaya Keynes. Should economics have fewer taboos? With Alvin Roth.   The Nobel laureate on the lines society draws around what can be bought and sold  

and here is the transcript:

Transcript: Should economics have fewer taboos? With Alvin Roth
Soumaya Keynes speaks to Alvin Roth, Nobel laureate and author of ‘Moral Economics’

"    Soumaya Keynes
So we always start this show with a silly question. So, on a scale of one to 10, how relaxed are you about marketisation? So 10, you’re extremely relaxed about having transactions in literally anything, and maybe five is the average person.

Alvin Roth
So I’m probably a 7.5, maybe 7.52."

 
 




 

Friday, May 15, 2026

The Organ Donation Dilemma: Ethics, Economics, and Life-Saving Solutions: Debate at Hopkins, today

Today's debate at Hopkins aims to focus on the proposed End Kidney Deaths Act.

 The Organ Donation Dilemma: Ethics, Economics, and Life-Saving Solutions
May 15, 2026 09:00 AM 
 

"With organ shortages claiming thousands of lives annually, this session explores whether carefully designed market mechanisms can increase donation rates while maintaining ethical standards and preventing exploitation.

Panelists:
-    Alexander Capron, USC Law/Bioethics  https://gould.usc.edu/faculty/profile/alexander-capron/ 

-    (TBC) Gabriel Danovitch, UCLA David Geffen School of Medicine, https://www.uclahealth.org/providers/gabriel-danovitch 

-    Kimberly Krawiec, UVA Law, https://www.law.virginia.edu/faculty/profile/kdk4q/1181653 

-    Elaine Perlman, President, Coalition to Modify NOTA and Executive Director, Waitlist Zero https://elaineperlman.com/ 

Moderator: 
-    Mario Macis, Johns Hopkins Carey Business School and HBHI https://mariomacis.net/index.html 

 

End Kidney Deaths Act summary /sites/default/files/2026-05/The%20End%20Kidney%20Deaths%20Act%20Summary.pdf

 

The list of 50+ supportive organizations, the legislative text, the podcast with Kim and Elaine and the Niskanen Center's economic analysis of the End Kidney Deaths Act 

Friday, May 8, 2026

It’s time to carefully but urgently rethink payments to kidney donors. My op-ed in the Washington Post

 This morning the Washington Post published my op-ed online (which is scheduled to appear in the print edition on Sunday). 800 words is hardly enough to explain why I think what I do...I could write a whole book about that.

But here's the op-ed: 

Why paying people to donate kidneys is a good idea

With 90,000 patients waiting for a kidney, compensating living donors would save lives.

 

 

Sunday, April 19, 2026

Funeral expenses for deceased organ donors in Taiwan

 In Taiwan, the Ministry of Health and Welfare helps pay for the funerals of deceased organ donors.

 From the Taiwan Organ Sharing Registry and Patient Autonomy Promotion Center

(2)  Grants and Assistance for Donors' Families

a.        Funeral Subsidies:
The MOHW provides funeral subsidies to the donor's family, including NT$50,000 for corneal donations and NT$100,000 for multiple organ donations in addition to the cornea.

b.        Farewell Care Service:
In order to express our gratitude to the organ donors and their families, we provided flower baskets and certificates of appreciation at the farewell ceremony of the donors. In addition to affirming the selfless dedication of the organ donors, we also thanked the family members for their decision.